v3.26.1
INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS - Investment in Precision Autoimmune Therapeutics Co Ltd (PAT) (Details)
¥ in Millions
1 Months Ended 12 Months Ended
Mar. 31, 2026
USD ($)
Mar. 31, 2026
CNY (¥)
Jan. 31, 2026
USD ($)
Jan. 31, 2026
CNY (¥)
Apr. 30, 2025
USD ($)
installment
Apr. 30, 2025
CNY (¥)
Aug. 31, 2024
USD ($)
Aug. 31, 2024
CNY (¥)
May 31, 2022
USD ($)
Dec. 31, 2025
USD ($)
installment
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2025
CNY (¥)
installment
Apr. 30, 2025
CNY (¥)
installment
Jul. 31, 2024
USD ($)
installment
Jul. 31, 2024
CNY (¥)
installment
May 31, 2022
CNY (¥)
Schedule of Investments                                    
Share of net loss of an equity investee                   $ 2,187,000 $ 1,189,000 $ 48,000            
Payments to acquire equity investments                   $ 1,624,000 1,370,000              
Precision Autoimmune Therapeutics Co., Ltd                                    
Schedule of Investments                                    
Equity ownership (as a percent)                   19.8876%       19.8876%        
Aggregate consideration for equity investment                 $ 3,000,000 $ 8,100,000       ¥ 56.8       ¥ 20.0
Share of net loss of an equity investee                       48,000 $ 800,000          
Number of installments | installment                   5       5        
Impairment of equity investment                       $ 2,000,000            
Payments to acquire equity investments             $ 5,100,000 ¥ 35.4                    
Precision Autoimmune Therapeutics Co., Ltd | Agreement one                                    
Schedule of Investments                                    
Share of net loss of an equity investee                   $ 2,200,000 $ 1,200,000              
Number of installments | installment                               3 3  
CASI China | Precision Autoimmune Therapeutics Co., Ltd                                    
Schedule of Investments                                    
Aggregate consideration for equity investment | ¥                             ¥ 28.4      
Percentage of equity held in joint venture                 15.00%                  
Percentage of interest in board seats                 33.33%                  
CASI China | Precision Autoimmune Therapeutics Co., Ltd | Agreement one                                    
Schedule of Investments                                    
Equity ownership (as a percent)                               19.8876% 19.8876%  
Aggregate consideration for equity investment                               $ 4,100,000 ¥ 28.4  
Payments to acquire equity investments         $ 1,400,000 ¥ 10.0 $ 1,400,000 ¥ 10.0                    
Equity method investment, ownership percentage         10.04%   5.17% 5.17%             10.04%      
CASI China | Precision Autoimmune Therapeutics Co., Ltd | Agreement Two                                    
Schedule of Investments                                    
Equity ownership (as a percent)         19.8876%                   19.8876%      
Aggregate consideration for equity investment         $ 4,100,000                   ¥ 28.4      
Number of installments | installment         2                   2      
CASI China | Precision Autoimmune Therapeutics Co., Ltd | Subsequent event | Agreement one                                    
Schedule of Investments                                    
Payments to acquire equity investments $ 1,200,000 ¥ 8.4                                
CASI China | Precision Autoimmune Therapeutics Co., Ltd | Subsequent event | Agreement Two                                    
Schedule of Investments                                    
Payments to acquire equity investments     $ 1,000,000 ¥ 7.0